Search

Aim: To assess the repertoire of antibody after complete vaccination of covishield concerning SARS-CoV-2. Study Design: Observational Study. Place And Duration of Study: The study was conducted in community area in Kerala for a duration of six months from January 2022 to June 2022. Methodology: The study was conducted in community area using 30 samples. The participants who fulfill inclusion criteria were selected and samples were collected by convenience sampling from the community and analyzed by the DDRC (Doctor’s Diagnostic and Research Centre) by using Electrochemiluminescence immunoassay. The collected data was statistically interpreted using SPSS software version 26.0 and the development of antibody after complete dose of vaccination was analyzed. Results: In this study blood samples were collected from 30 subjects fulfilling the inclusion criteria. Out of 30 subjects, 12 were females and 18 were males. The mean interval between the doses were 91.63. All the 30 samples produced antibodies greater than 250 U/ml. The study helps to provide qualitative evidence that the vaccine produces antibody response. Conclusion: Covid-19 vaccines are being available into public for human use after limited testing and trials. Many efforts are being directed towards development of vaccines against SARS-CoV-2. The information made available from this study can be utilized to prove that covishield vaccine is effective for producing antibodies. Most of the people took vaccines since it was mandatory rather than concerning its benefits. By providing evidence of antibody development after complete vaccination can improve the public attitude towards the vaccination.